Role of GABA in anxiety and depression

Depression and Anxiety

Volumn 24, Issue 7, 2007, Pages 495-517

  Kalueff, Allan V ^a   Nutt, David J ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Anxiety; Benzodiazepine receptors; Common pathogenesis; Depression; GABA

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINO 3 PHENYLBUTYRIC ACID; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ADINAZOLAM; ALCOHOL; ALPRAZOLAM; AMINOOXYACETIC ACID; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; DIAZEPAM; GABAPENTIN; MUSCIMOL; NEUROTRANSMITTER; OXCARBAZEPINE; PENTOBARBITAL; PROGABIDE; PROGESTERONE; SEROTONIN UPTAKE INHIBITOR; TIAGABINE; VALPROIC ACID; VIGABATRIN;

AMYGDALOID NUCLEUS; ANXIETY DISORDER; BRAIN REGION; DEPRESSION; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EXPERIMENTATION; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; GENE CLUSTER; GENE EXPRESSION; GENE MAPPING; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; MENTAL DISEASE; MENTAL STRESS; MESENCEPHALON; METABOLISM; MOLECULAR MECHANICS; NEUROBIOLOGY; NEUROCHEMISTRY; NEUROIMAGING; NONHUMAN; PATHOGENESIS; POSTTRAUMATIC STRESS DISORDER; PREFRONTAL CORTEX; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; REGULATORY MECHANISM; REVIEW; THEORETICAL STUDY;

ANIMALS; ANXIETY DISORDERS; BRAIN; DEPRESSIVE DISORDER; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; GAMMA-AMINOBUTYRIC ACID; HUMANS; RECEPTORS, GABA-A;

EID: 36048976944     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20262     Document Type: Review

References (344)

1. Aley KO, Kulkarni SK. 1989. GABA-mediated modification of despair behavior in mice. Naunyn Schmied Arch Pharmacol 339:306-311.
2. Altshuler LL, Keck PE Jr, McElroy SL, Suppes T, Brown ES, Denicoff K, Frye M, Gitlin M, Hwang S, Goodman R, Leverich G, Nolen W, Kupka R, Post R. 1999. Gabapentin in the acute treatment of refractory bipolar disorder. Bipolar Disord 1:61-65.
3. Amano K, Tanikama T, Iseki H, Kawabatake H, Notani M, Kawamura H. 1978. Single neuron analysis of the midbrain tegmentum: rostral mesencephalic reticulotomy of pain relief. Appl Neurophysiol 41:66-78.
4. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. 1999. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160:1-12.
5. Argyropoulos SV, Nutt DJ. 1997. Anhedonia and chronic mild stress model in depression. Psychopharmacology 134:333-336.
6. Argyropoulos SV, Nutt DJ. 1999. The use of benzodiazepines in anxiety and other disorders. Eur Neuropsychopharmacol 9(Suppl 6):S407-S412.
7. Argyropoulos SV, Sandford JJ, Nutt DJ. 2000. The psychobiology of anxiolytic drug. 2. Pharmacological treatments of anxiety. Pharmacol Ther 88:213-227.
8. Atack JR. 2003. Anxioselective compounds acting at the GABAa receptor benzodiazepine binding site. Curr Drug Targ CNS Neurol Disord 2:213-232.
9. Atack JR. 2005. The benzodiazepine binding site of GABA-A receptors as a target for the development of novel anxiolytics. Expert Opin Investig Drugs 14:599-616.
10. Atack JR, Hutson PH, Collinson N, Marcshall G, Bentley G, Moyes C, Cook SM, Collins I, Wafford K, McKerman RM, Dawson GR. 2005. Anxiogenic properties of an inverse agonist selective for α3 subunit-containing GABAA receptors. Br J Pharmacol 144: 357-366.
11. Audi EA, Graeff FG. 1984. Benzodiazepine receptors in the periaqueductal grey mediate anti-aversive drug action. Eur J Pharmacol 103:279-285.
12. Audi EA, Graeff FG. 1987. GABAA receptors in the midbrain central grey mediate the antiaversive action of GABA. Eur J Pharmacol 135: 225-229.
13. Bai F, Li M, Clay M, Lindstrom T, Skolnick P. 2001. Intra- and interstrain differences in models of "behavioral despair.". Pharmacol Biochem Behav 70:187-192.
14. Banks MI, White JA, Pearce RA. 2000. Interactions between distinct GABA(A) circuits in hippocampus. Neuron 25:449-457.
15. Barad M. 2005. Fear extinction in rodents: basic insight to clinical promise. Curr Opin Neurobiol 15:710-715.
16. Barbaccia ML, Costa E, Ferrero P, Guidotti A, Roy A, Sunderland T, Pickar D, Paul SM, Goodwin FK. 1986. Diazepam-binding inhibitor. A brain neuropeptide present in human spinal fluid: studies in depression, schizophrenia, and Alzheimer's disease. Arch Gen Psychiatry 43:1143-1147.
17. Barbaccia ML, Lello S, Sidiropoulou T, Cocco T, Sorge RP, Cocchiarale A, Piermarini V, Sabato AF, Trabucchi M, Romanini C. 2000. Plasma 5alpha-androstane-3alpha,17betadiol, an endogenous steroid that positively modulates GABA(A) receptor function, and anxiety: a study in menopausal women. Psychoneuroendocrinology 25:659-675.
18. Bartholini G. 1984. Experimental basis for the antidepressant action of the GABA receptor agonist progabide. Neurosci Lett 47: 351-355.
19. Battaglia M, Ogliari A. 2005. Anxiety and panic: from human studies to animal research and back. Neurosci Biobehav Rev 29:169-179.
20. Beijamini V, Skalisz LL, Joca SR, Andreatini R. 1998. The effect of oxcarbazepine on behavioral despair and learned helplessness. Eur J Pharmacol 347:23-27.
21. Beleih D, Lambert JJ. 2005. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci 6:565-575.
22. Bell MV, Bloomfield J, McKinley M, Patterson MN, Darlison MG, Barnard EA, Davies KE. 1989. Physical linkage of a GABAA receptor subunit gene to the DXS374 locus in human Xq28. Am J Hum Genet 45:883-888.
23. Belozertseva IV, Andreev BV. 1997. A pharmaco-ethological study of the GABA-ergic mechanisms regulating the depression-like behavior of mice. Zh VND Im I P Pavlova 47:1024-1031.
24. Belzung C. 2001. Rodent models of anxiety-like behaviors: are they predictive for compounds acting via non-benzodiazepine mechanisms? Curr Opin Investig Drugs 2:1108-1111.
25. Besag FM. 2001. Behavioral effects of the new anticonvulsants. Drug Saf 24:513-536.
26. Bhagwagar Z, Wylezinska M, Taylor M, Jezzard P, Matthews PM, Cowen PJ. 2004. Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. Am J Psychiatry 161:368-370.
27. Birkenhager TK, Moleman P, Nolen WA. 1995. Benzodiazepines for depression? A review of the literature. Int Clin Psychopharmacol 10:181-195.
28. Bjork JM, Moeller FG, Kramer GL, Kram M, Suris A, Rush AJ, Petty E 2001. Plasma GABA levels correlate with aggressiveness in relatives of patients with unipolar depressive disorder. Psychiatry Res 101:131-136.
29. Boehm SL, Ponomarev I, Jennings AW, Whitting PJ, Rosahl TW, Garrett EM, Blednov YA, Harris A. 2004. γ-Aminobutyric acid A receptor subunit mutant mice: new perspectives on alcohol actions. Biochem Pharmacol 68:1581-1602.
30. Borsini F, Evangelista S, Meli A. 1986. Effect of GABAergic drugs in the behavioral 'despair' test in rats. Eur J Pharmacol 121: 265-268.
31. Borsini F, Mancinelli A, D'Aranno V, Evangelista S, Meli A. 1988. On the role of endogenous GABA in the forced swimming test in rats. Pharmacol Biochem Behav 29:275-279.
32. Borsini F, Podhorna J, Marazziti D. 2002. Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology 163:121-141.
33. Boshuisen ML, Ter Horst GJ, Paans AM, Reinders AA, den Boer JA. 2002. rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest. Biol Psychiatry 52:126-135.
34. Bourin M, Colombel MC, Malinge M, Bradwejn J. 1991. Clonidine as a sensitizing agent in the forced swimming test for revealing antidepressant activity. J Psychiatry Neurosci 16:199-203.
35. Bovier P, Broekkamp CL, Lloyd KG. 1982. Enhancing GABAergic transmission reverses the aversive state in rats induced by electrical stimulation of the periaqueductal grey region. Brain Res 248: 313-320.
36. Brambilla P, Perez J, Barale F, Schettini G, Soares JC. 2003. GABAergic dysfunction in mood disorders. Mol Psychiatry 8: 721-737, 715.
37. Brandao ML, Troncoso AC, de Souza Silva MA, Huston JP. 2003. The relevance of neuronal substrates of defense in the midbrain tectum to anxiety and stress: empirical and conceptual considerations. Eur J Pharmacol 463:225-233.
38. Bremner JD, Innis RB, Salomon RM, Staib LH, Ng CK, Miller HL, Bronen RA, Krystal JH, Duncan J, Rich D, Price LH, Malison R, Dey H, Soufer R, Charney DS. 1997. Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch Gen Psychiatry 54:364-374.
39. Bremner JD, Narayan M, Staib LH, Southwick SM, McGlashan T, Charney DS. 1999. Neural correlates of memories of childhood sexual abuse in women with and without posttraumatic stress disorder. Am J Psychiatry 156:1787-1795.
40. Bremner JD, Innis RB, White T, Fujita M, Silbersweig D, Goddard AW, Staib L, Stern E, Cappiello A, Woods S, Baldwin R, Charney DS. 2000a. SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry 47: 96-106.
41. Bremner JD, Innis RB, Southwick SM, Staib L, Zoghbi S, Charney DS. 2000b. Decreased benzodiazepine receptor binding in prefrontal cortex in combat-related posttraumatic stress disorder. Am J Psychiatry 157:1120-1126.
42. Briones-Aranda A, Rocha L, Picazo O. 2005. Alterations in GABAergic function following forced swimming stress. Pharmacol Biochem Behav 80:463-470.
43. Buckle VJ, Fujita N, Ryder-Cook AS, Deny JM, Barnard PJ, Lebo RV, Schofield PR, Seeburg PH, Bateson AN, Darlison MG. 1989. Chromosomal localization of GABAA receptor subunit genes: relationship to human genetic disease. Neuron 3:647-654.
44. Bueno CH, Zangrossi H Jr, Nogueira RL, Soares VP, Viana MB. 2005a. Panicolytic-like effect induced by the stimulation of GABAA and GABAB receptors in the dorsal periaqueductal grey of rats. Behav Brain Res 21:65-72.
45. Bueno CH, Zangrossi H Jr, Viana MB. 2005b. The inactivation of the basolateral nucleus of the rat amygdala has an anxiolytic effect in the elevated T-maze and light/dark transition tests. Braz J Med Biol Res 38:1697-1701.
46. Bullock AE, Clark AL, Grady SR, Robinson SF, Slobe BS, Marks MJ, Collins AC. 1997. Neurosteroids modulate nicotinic receptor function in mouse striatal and thalamic synaptosomes. J Neurochem 68:2412-2423.
47. Caetano SC, Hatch JP, Brambilla P, Sassi RB, Nicoletti M, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC. 2005. Anatomical MRI study of hippocampus and amygdala in patients with current and remitted major depression. Psychiatry Res 132: 141-147.
48. Caldecott-Hazard S, Mazziotta J, Phelps M. 1988. Cerebral correlates of depressed behavior in rats, visualized using 14C-2-deoxyglucose autoradiography. J Neurosci 8:1951-1961.
49. Caldji C, Diorio J, Anisman H, Meaney MJ. 2004. Maternal behavior regulates benzodiazepine/GABAA receptor subunit expression in brain regions associated with fear in BALB/c and C57BL/6 mice. Neuropsychopharmacology 29:1344-1352.
50. Canli T, Cooney RE, Goldin P, Shah M, Sivers H, Thomason ME, Whitfield-Gabrieli S, Gabrieli JD, Gotlib IH. 2005. Amygdala reactivity to emotional faces predicts improvement in major depression. Neuroreport 16:1267-1270.
51. Cannizzaro G, Flugy A, Cannizzaro C, Gagliano M, Sabatino M. 1993. Effects of desipramine and alprazolam in the forced swim test in rats after long-lasting termination of chronic exposure to Picrotoxin and pentylenetetrazol. Eur Neuropsychopharmacol 3: 477-484.
52. Carobrez AP, Bertoglio LJ. 2005. Etiological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. Neurosci Biobehav Rev 29:1193-1205.
53. Carrasco GA, Van de Kar LD. 2003. Neuroendocrine pharmacology of stress. Eur J Pharmacol 463:235-272.
54. Chandra D, Korpi ER, Miralies CP, De Blas AL, Homanics GE. 2005. GABAA receptor γ2 subunit knockdown mice have enhanced anxiety-like behavior but unaltered hypnotic response to benzodiazepines. BMC Neurosci 6:30.
55. Chang L, Cloak CC, Ernst T. 2003. Magnetic resonance spectroscopy studies of GABA in neuropsychiatrie disorders. J Clin Psychiatry 64(Suppl 3):7-14.
56. Chapouthier G, Venault P. 2002. GABA-A receptor complex and memory processes. Curr Top Med Chem 2:841-851.
57. Chhatwal JP, Myers KM, Ressler KJ, Davis M. 2005. Regulation of gephyrin and GABAA receptor binding within the amygdala after fear acquisition and extinction. J Neurosci 25:502-506.
58. Chopra K, Kunchandy J, Kulkarni SK. 1988. Benzodiazepine inverse agonist FG-7142-induced delayed behavioral depression in mice. Arch Int Pharmacodyn Ther 294:56-63.
59. Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, Myers RM, Bunney WE, Aldi H, Watson SJ, Jones EG. 2005. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA 102: 15653-15658.
60. Clement Y, Chapouthier G. 1998. Biological bases of anxiety. Neurosci Biobehav Rev 22:623-633.
61. Collinson N, Kuenzi FM, Jarolimek W, Maubach KA, Cothliff R, Sur C, Smith A, Out FM, Howell O, Atack JR, McKernan RM, Seabrook GR, Dawson GR, Whiting PJ, Rosahl TW. 2002. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the α5 subunit of the GABAA receptor. J Neurosci 22:5572-5580.
62. Connor KM, Davidson JRT, Weisler RH, Zhang W, Abraham K. 2006. Tiagabin for post-traumatic stress disorder: effect of open-label and double-blind discontinuation treatment. Psychopharmacology 184:21-25.
63. Coplan JD, Lydiard RB. 1998. Brain circuits in panic disorder. Biol Psychiatry 44:1264-1276.
64. Crane D. 2003. Tiagabine for the treatment of anxiety. Depress Anxiety 18:51-52.
65. Crawley JN. 1999. Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 835:18-26.
66. Crawley JN. 2000. What's wrong with my mouse? Behavioral phenotyping of transgenic and knockout mice. New York: Wiley-Liss.
67. Crestani F, Lorez M, Baer K, Essrich C, Benke D, Laurent JP, Belzung C, Fritschy JM, Luscher B, Mohler H. 1999. Decreased GABA-A receptor clustering results in enhanced anxiety and bias for threat cues. Nat Neurosci 2:833-839.
68. Crowley JJ, Lucki I. 2005. Opportunities to discover genes regulating depression and antidepressant response from rodent behavioral genetics. Curr Pharm Design 11:157-169.
69. Crunelli V, Emri Z, Leresche N. 2006. Unravelling the brain targets of gamma-hydroxybutyric acid. Curr Opin Pharmacol 6:1-9.
70. Cryan JF, Holmes A. 2005. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 4:775-790.
71. Cryan JF, Kaupmann K. 2005. Don't worry "B" happy: a role for GABAB receptors in anxiety and depression. Trends Pharmacol Sci 26: 36-43.
72. Cryan JF, Mombereau C. 2004. In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry 9:326-357.
73. Cryan JF, Markou A, Lucki I. 2002. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23:238-245.
74. Cryan JF, Valentino RJ, Lucki I. 2005. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 29: 547-569.
75. Dagnino-Subiabre A, Terreros G, Carmona-Fontaine C, Zepeda R, Orellana JA, Diaz-Veliz G, Mora S, Aboitiz F. 2005. Chronic stress impairs acoustic conditioning more than visual conditioning in rats: morphological and behavioral evidence. Neuroscience 135: 1067-1074.
76. Dalvi A, Rodgers RJ. 1996. GABAergic influences on plus-maze behavior in mice. Psychopharmacology 128:380-397.
77. Daly RC, Schmidt PJ, Davis CL, Danaceau MA, Rubinow DR. 2001. Effects of gonadal steroids on peripheral benzodiazepine receptor density in women with PMS and controls. Psychoneuroendocrinology 26:539-549.
78. Davidson RJ. 2002. Anxiety and affective style: role of prefrontal cortex and amygdala. Biol Psychiatry 51:68-80.
79. Davidson RJ, Lewis DA, Alloy LB, Amaral DG, Bush G, Cohen JD, Drevets WC, Farah MJ, Kagan J, McClelland JL, Nolen-Hoeksema S, Peterson BS. 2002. Neural and behavioral substrates of mood and mood regulation. Biol Psychiatry 52:478-502.
80. Davies M. 2003. The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. J Psychiatry Neurosci 28:263-274.
81. Davis M, Whalen PJ. 2001. The amygdala: vigilance and emotion. Mol Psychiatry 6:13-34.
82. De La Garza, Mahoney JJ. 2004. A distinct neurochemical profile in WKY rats at baseline and in response to acute stress: implications for animal models of anxiety and depression. Brain Res 1021: 209-218.
83. Dennis T, Beauchemin V, Lavoie N. 1994. Antidepressant-induced modulation of GABAA receptors and beta-adrenoceptors but not GABAB receptors in the frontal cortex of olfactory bulbectomised rats. Eur J Pharmacol 262:143-148.
84. Dong E, Matsumoto K, Tohda M, Kaneko Y, Watanabe H. 1999. Diazepam binding inhibitor (DBI) gene expression in the brains of socially isolated and group-housed mice. Neurosci Res 33: 171-177.
85. Do-Rego JC, Suaudeau C, Chapouthier G, Costentin J. 2002. Mouse lines differing in sensitivity to beta-CCM differ in tasks used for testing antidepressants. Pharmacol Biochem Behav 72:411-416.
86. Drake RG, Davis LL, Cates ME, Jewell ME, Ambrose SM, Lowe JS. 2003. Baclofen treatment for chronic posttraumatic stress disorder. Ann Pharmacother 37:1177-1181.
87. Drevets WC. 1999. Prefrontal cortical-amygdalar metabolism in major depression. Ann N Y Acad Sci 877:614-637.
88. Drigues N, Poltyrev T, Bejar C, Weinstock M, Youdim MB. 2003. cDNA gene expression profile of rat hippocampus after chronic treatment with antidepressant drugs. J Neural Transm 110: 1413-1436.
89. Drugan RC, Maier SF, Skolnick P, Paul SM, Crawley JN. 1985. An anxiogenic benzodiazepine receptor ligand induces learned helplessness. Eur J Pharmacol 113:453-457.
90. Drugan RC, Morrow AL, Weizman R, Weizman A, Deutsch SI, Crawley JN, Paul SM. 1989. Stress-induced behavioral depression in the rat is associated with a decrease in GABA receptor-mediated chloride ion flux and brain benzodiazepine receptor occupancy. Brain Res 487:45-51.
91. Drugan RC, Paul SM, Crawley JN. 1993. Decreased forebrain [35S]TBPS binding and increased [3H]muscimol binding in rats that do not develop stress-induced behavioral depression. Brain Res 631:270-276.
92. Dubrovsky BO. 2005. Steroids, neuroactive steroids and neurosteroids in psychopathology. Prog Neuropsychopharmacol Biol Psychiatry 29:169-192.
93. Edenberg HJ, Foroud T, Conneally PM, Sorbel JJ, Carr K, Crose C, Willig C, Zhao J, Miller M, Bowman E, Mayeda A, Rau NL, Smiley C, Rice JP, Goate A, Reich T, Stine OC, McMahon F, DePaulo JR, Meyers D, Detera-Wadleigh SD, Goldin LR, Gershon ES, Blehar MC, Nurnberger JI. 1997. Initial genomic scan of the NIMH genetics initiative bipolar pedigree: chromosomes 3, 5, 15, 16, 17, and 22. Am J Med Genet 74:238-246.
94. Emrich HM, von Zerssen D, Kissling W, Moller HJ, Windorfer A. 1980. Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch Psychiatr Nervenkr 229:1-16.
95. Enoch MA. 2003. Pharmacogenomics of alcohol response and addiction. Am J Pharmacogenomics 3:217-232.
96. Epperson CN, Gueorguieva R, Czarkowski KA, Stiklus S, Sellers E, Krystal JH, Rothman DL, Mason GF. 2006. Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study. Psychopharmacology 186:425-433.
97. Erickson K, Drevets W, Schulkin J. 2003. Glucocorticoid regulation of diverse cognitive functions in normal and pathological emotional states. Neurosci Biobehav Rev 27:233-246.
98. Eser D, Schule C, Romeo E, Baghai TC, di Michele F, Pasini A, Zwanzger P, Padberg F, Rupprecht R. 2006a. Neuropsychopharmacological properties of neuroactive steroids in depression and anxiety disorders. Psychopharmacology 186:373-387.
99. Eser D, Romeo E, Baghai TC, di Michele F, Schule C, Pasini A, Zwanzger P, Padberg F, Rupprecht R. 2006b. Neuroactive steroids as modulators of depression and anxiety. Neuroscience 138: 1041-1048.
100. Estrada-Camarena E, Contreras CM, Saavedra M, Luna-Baltazar I, Lopez-Rubalcava C. 2002. Participation of the lateral septal nuclei (LSN) in the antidepressant-like actions of progesterone in the forced swimming test (FST). Behav Brain Res 134:175-183.
101. Fatemi SH, Stary JM, Earle JA, Araghi-Nikham M, Eagan E. 2005. GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 and Reelin proteins in cerebellum. Schizophr Res 72:109-122.
102. Fernandez Teruel A, Boix F, Escorihuela RM, Yanez P, Tobena A. 1988. Sodium valproate reduces immobility in the behavioral 'despair' test in rats. Eur J Pharmacol 152:1-7.
103. Feusner J, Ritchie T, Lawford B, Young RM, Kann B, Nobre EP. 2001. GABAA receptor β3 subunit gene and psychiatric morbidity in a post-traumatic stress disorder population. Psychiatry Res 104: 109-117.
104. File SE, Mabbutt PS, Andrews N. 1991. Diazepam withdrawal responses measured in the social interaction test of anxiety and their reversal by baclofen. Psychopharmacology 104:62-66.
105. File SE, Zharkovsky A, Hitchcott PK. 1992. Effects of nitrendipine, chlordiazepoxide, flumazenil and baclofen on the increased anxiety resulting from alcohol withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 16:87-93.
106. Finn DA, Rutledge-Gorman MT, Crabbe JC. 2003. Genetic animal models of anxiety. Neurogenetics 4:109-135.
107. Flint J. 2002. Genetic effects on an animal model of anxiety. FEBS Lett 529:131-134.
108. Flint J. 2003. Animal models of anxiety and their molecular dissection. Semin Cell Dev Biol 14:37-42.
109. Flugy A, Gagliano M, Cannizzaro C, Novara V, Cannizzaro G. 1992. Antidepressant and anxiolytic effects of alprazolam versus the conventional antidepressant desipramine and the anxiolytic diazepam in the forced swim test in rats. Eur J Pharmacol 214: 233-238.
110. Fong GCY, Cheung BMY, Kumana CR. 2003. Gabapentin. Med Prog 2:1-8.
111. Freeman HL. 1997. Advantages and limitations of the concept of antidepressant therapy. Eur Neuropsychopharmacol 7(Suppl 3): S315-S321.
112. Freeman MP, Freeman SA, McElroy SL. 2002. The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. J Affect Disord 68:1-23.
113. Gajwani P, Forsthoff A, Muzina D, Amann B, Gao K, Elhaj O, Calabrese JR, Grunze H. 2005. Antiepileptic drugs in mood-disordered patients. Epilepsia 46(Suppl 4):38-44.
114. George MS, Guidotti A, Rubinow D, Pan B, Mikalauskas K, Post RM. 1994. CSF neuroactive steroids in affective disorders: pregnenolone, progesterone, and DBI. Biol Psychiatry 35:775-780.
115. Geyer MA, Markou A. 1995. Animal models of psychiatric disorders. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, p 787-798.
116. Ghaemi SN, Katzow JJ, Desai SP, Goodwin FK. 1998. Gabapentin treatment of mood disorders: a preliminary study. J Clin Psychiatry 59:426-429.
117. Gill KJ, Boyle AE. 2005. Quantitative trait loci for novelty/stress- induced locomotor activation in recombinant inbred (RI) and recombinant congenic (RC) strains of mice. Behav Brain Res 161: 113-124.
118. Gillespie NA, Kirk KM, Evans DM, Heath AC, Hickie IB, Martin NG. 2004. Do the genetic or environmental determinants of anxiety and depression change with age? A longitudinal study of Australian twins. Twin Res 7:39-53.
119. Gilmer WS. 2001. Anticonvulsants in the treatment of mood disorders: assessing current and future roles. Expert Opin Pharmacother 2:1597-1608.
120. Goddard AW, Mason GF, Appel M, Rothman DL, Gueorguieva R, Behar KL, Krystal JH. 2004. Impaired GABA neuronal response to acute benzodiazepine administration in panic disorder. Am J Psychiatry 161:2186-2193.
121. Gomez R, Vargas CR, Wajner M, Barros HM. 2003. Lower in vivo brain extracellular GABA concentration in diabetic rats during forced swimming. Brain Res 968:281-284.
122. Grachev ID, Apkarian AV 2000. Anxiety in healthy humans is associated with orbital frontal chemistry. Mol Psychiatry 5: 482-488.
123. Graeff FG, Brandao ML, Audi EA, Schutz MT. 1986. Modulation of the brain aversive system by GABAergic and serotonergic mechanisms. Behav Brain Res 21:65-72.
124. Graeff FG, Silveira MC, Nogueira RL, Audi EA, Oliveira RM. 1993. Role of the amygdala and periaqueductal gray in anxiety and panic. Behav Brain Res 58:123-131.
125. Guidotti A. 1991. Role of DBI in brain and its posttranslational processing products in normal and abnormal behavior. Neuropharmacology 30:1425-1433.
126. Guidotti A, Auta J, Davis JM, Di-Giorgi-Gerevini V, Dwivedi Y, Grayson DR, Impagnatiello F, Pandey G, Pesold C, Sharma R, Uzunov D, Costa E. 2000. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 57:1061-1069.
127. Guidotti A, Dong E, Matsumoto K, Pinna G, Rasmusson AM, Costa E. 2001. The socially-isolated mouse: a model to study the putative role of allopregnanolone and 5alpha-dihydroprogesterone in psychiatric disorders. Brain Res Rev 37:110-115.
128. Gulinello M, Gong QH, Li X, Smith SS. 2001. Short-term exposure to a neuroactive steroid increases alpha4 GABA(A) receptor subunit levels in association with increased anxiety in the female rat. Brain Res 910:55-66.
129. Hayase T, Yamamoto Y, Yamamoto K. 2002. Toxic cocaine- and convulsant-induced modification of forced swimming behaviors and their interaction with ethanol: comparison with immobilization stress. BMC Pharmacol 2:19.
130. Henkel V, Baghai TC, Eser D, Zill P, Mergl R, Zwanzger P, Schulle C, Bottlender R, Jager M, Rupprecht R, Hegerl U, Moller HJ, Bondy B. 2004. The gamma amino butyric acid (GABA) receptor alpha-3 subunit gene polymorphism in unipolar depressive disorder: a genetic association study. Am J Med Genet 126: 82-87.
131. Herman JP, Renda A, Bodie B. 2003. Norepinephrine-gamma-aminobutyric acid (GABA) interaction in limbic stress circuits: effects of reboxetine on GABAergic neurons. Biol Psychiatry 53:166-174.
132. Hickie I, Naismith S, Ward PB, Turner K, Scott E, Mitchell P, Wilhelm K, Parker G. 2005. Reduced hippocampal volumes and memory loss in patients with early- and late-onset depression. Br J Psychiatry 186:197-202.
133. Hilakivi LA, Taira T, Hilakivi I, Loikas P. 1988. Neonatal treatment with monoamine uptake inhibitors alters later response in behavioral 'despair' test to beta and GABA-B receptor agonists. Pharmacol Toxicol 63:57-61.
134. Hinderer SR. 1990. The supraspinal anxiolytic effect of baclofen for spasticity reduction. Am J Phys Med Rehabil 69:254-258.
135. Hirani K, Khisti RT, Chopde CT 2002. Behavioral action of ethanol in Porsolt's forced swim test: modulation by 3 alpha-hydroxy-5 alpha-pregnan-20- one. Neuropharmacology 43:1339-1350.
136. Hirani K, Sharma AN, Jain NS, Ugale RR, Chopde CT 2005. Evaluation of GABAergic neuroactive steroid 3alpha-hydroxy-5alpha-pregnane-20-one as a neurobiological substrate for the anti-anxiety effect of ethanol in rats. Psychopharmacology 180: 267-278.
137. Hisama FM, Gruen JR, Choi J, Huseinovic M, Grigorenko EL, Pauls D, Mattson RH, Gelernter J, Wood FB, Goei VL. 2001. Human GABAA receptor 1 gene: eight novel sequence variants. Human Mutat 17:349-350.
138. Ho YJ, Eichendorff J, Schwaning RK. 2002. Individual response profiles of male Wistar rats in animal models for anxiety and depression. Behav Brain Res 136:1-12.
139. Horiuchi Y, Nakayama J, Ishiguro H, Ohtsuki T, Detera-Wadleigh S, Toyota T, Yamada K, Nankai M, Shibuya H, Yoshikawa T, Arinami T 2004. Possible association between a haplotype of the GABA-A receptor α1 subunit gene (GABRA1) and mood disorders. Biol Psychiatry 55:40-45.
140. Jamous A, Kennedy P, Psychol C, Grey N. 1994. Psychological and emotional effects of the use of oral baclofen: a preliminary study. Paraplegia 32:349-353.
141. Jardim MC, Guimaraes FS. 2001. GABAergic and glutamatergic modulation of exploratory behavior in the dorsomedial hypothalamus. Pharmacol Biochem Behav 69:579-584.
142. Jasnow AM, Huhman KL. 2001. Activation of GABA(A) receptors in the amygdala blocks the acquisition and expression of conditioned defeat in Syrian hamsters. Brain Res 920:142-150.
143. Joca SR, Skalisz LL, Beijamini V, Vital MA, Andreatini R. 2000. The antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission. Eur Neuropsychopharmacol 10: 223-238.
144. Kalisch R, Salome N, Platzer S, Wigger A, Czisch M, Sommer W, Singewald N, Heilig M, Berthele A, Holsboer F, Landgraf R, Auer DP. 2004. High trait anxiety and hyporeactivity to stress of the dorsomedial prefrontal cortex: a combined phMRI and Fos study in rats. Neuroimage 23:382-391.
145. Kalisch R, Schubert M, Jacob W, Kessler MS, Hemauer R, Wigger A, Landgraf R, Auer DP. 2005. Anxiety and hippocampus volume in the rat. Neuropsychopharmacology 1-8.
146. Kalueff AV 1997. New problems in GABAergic pharmacology of anxiety. Eksp Klin Farmakol 60:3-7.
147. Kalueff A, Nutt DJ. 1996. Role of GABA in memory and anxiety. Depress Anxiety 4:100-110.
148. Kamei C, Masuda Y, Oka M, Shimizu M. 1975. Effects of antidepressant drugs on amygdaloid after-discharge in rats. Jpn J Pharmacol 25:359-365.
149. Kaschka W, Feistel H, Ebert D. 1995. Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT. J Psychiatr Res 29:427-434.
150. Kash SF, Tecott LH, Hodge C, Baekkeskov S. 1999. Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci USA 96:1698-1703.
151. Katsura M, Mohri Y, Shuto K, Tsujimura A, Ukai M, Ohkuma S. 2002. Psychological stress, but not physical stress, causes increase in diazepam binding inhibitor (DBI) mRNA expression in mouse brains. Mol Brain Res 104:103-109.
152. Kaufmann KR. 1998. Adjunctive tiagabine treatment of psychiatric disorders: three cases. Ann Clin Psychiatry 10:181-184.
153. Kelly JP, Wrynn AS, Leonard BE. 1997. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 74: 299-316.
154. Kendler KS, Heath A, Martin NG, Eaves LJ. 1986. Symptoms of anxiety and depression in a volunteer twin population. The etiologic role of genetic and environmental factors. Arch Gen Psychiatry 43:213-221.
155. Kendler KS, Heath AC, Martin NG, Eaves LJ. 1987. Symptoms of anxiety and symptoms of depression. Same genes, different environments? Arch Gen Psychiatry 44:451-457.
156. Keros S, Hablitz JJ. 2005. Subtype-specific GABA transporter antagonists synergetically modulate phasic and tonic GABAA conductance in rat neocortex. J Neurophysiol 94: 2073-2085.
157. Ketter TA, Wang PW 2002. Predictors of treatment response in bipolar disorders: evidence from clinical and brain imaging studies. J Clin Psychiatry 63(Suppl 3):21-25.
158. Khisti RT, Chopde CT, Jain SP. 2000. Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test. Pharmacol Biochem Behav 67:137-143.
159. Khisti RT, Penland SN, VanDoren MJ, Grobin AC, Morrow AL. 2002. GABAergic neurosteroid modulation of ethanol actions. World J Biol Psychiatry 3:87-95.
160. Killgore WD, Yurgelun-Todd DA. 2004. Activation of the amygdala and anterior cingulate during nonconscious processing of sad versus happy faces. Neuroimage 21:1215-1223.
161. Killgore WD, Yurgelun-Todd DA. 2005. Social anxiety predicts amygdala activation in adolescents viewing fearful faces. Neuroreport 16:1671-1675.
162. Korpi ER, Sinkkonen ST. 2006. GABAa receptor subtypes as targets for neuropsychiatrie drug development. Pharmacol Ther 109: 12-32.
163. Korpi ER, Grunder G, Luddens H. 2002. Drug interactions at GABA(A) receptors. Prog Neurobiol 67:113-159.
164. Kosel M, Rudolph U, Wielepp P, Luginbuhl M, Schmitt W, Fisch HU, Schlaeper TE. 2004. Diminished GABAa receptor-binding capacity and a DNA base substitution in a patient with treatment-resistant depression and anxiety. Neuropsychopharmacology 29: 347-350.
165. Kram ML, Kramer GL, Steciuk M, Ronan PJ, Petty F. 2000. Effects of learned helplessness on brain GABA receptors. Neurosci Res 38: 193-198.
166. Kroes RA, Panksepp J, Burgdorf J, Otto NJ, Moskal JR. 2005. Modeling depression: social dominance-submission gene expression patterns in rat neocortex. Neuroscience 137:37-49.
167. Krupitskii EM, Burakov AM, Ivanov VB, Karandashova GF, Lapin IP, Grinenko AIa, Borodkin IuS. 1994. The use of baclofen for treating affective disorders in alcoholism. Zh Nevropatol Psikhiatr Korsakov 94:57-61.
168. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF. 2002. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 7(Suppl 1):S71-S80.
169. 123I]iomazenil SPECT. Biol Psychiatry 54: 792-799.
170. Lang AP, de Angelis L. 2003. Experimental anxiety and antiepileptics: the effects of valproate and vigabatrin in the mirrored chamber test. Methods Find Exp Clin Pharmacol 25:265-271.
171. Lapin I. 2001. Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Rev 7:471-481.
172. Lappalainen J, Sanacora G, Kranzler HR, Malison R, Hibbard ES, Price LH, Krystal J, Gelernter J. 2004. Mutation screen of the glutamate decarboxylase-67 gene and haplotype association to unipolar depression. Am J Med Genet 124:81-86.
173. Lemoine P, Boulenger JP, Caillard V, Tanne N, Bonnet D. 1991. Compared efficacy of prazepam and clomipramine in major depression with anxiety: a multicenter controlled study. Pharmacopsychiatry 24:175-179.
174. Leung JW, Xue H. 2003. GABAergic functions and depression: from classical therapies to herbal medicine. Curr Drug Targets CNS Neurol Disord 2:363-374.
175. Levesque J, Eugene F, Joanette Y, Paquette V, Mensour B, Beaudoin G, Leroux JM, Bourgouin P, Beauregard M. 2003. Neural circuitry underlying voluntary suppression of sadness. Biol Psychiatry 53: 502-510.
176. Linthorst AC, Penalva RG, Flachskamrn C, Holsboer F, Reul JM. 2002. Forced swim stress activates rat hippocampal serotonergic neurotransmission involving a corticotropin-releasing hormone receptor-dependent mechanism. Eur J Neurosci 16: 2441-2452.
177. Lloyd KG, Morselli PL, Depoortere H, Fournier V, Zivkovic B, Scatton B, Broekkamp C, Worms P, Bartholini G. 1983. The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials. Pharmacol Biochem Behav 18:957-966.
178. Lloyd KG, Thuret F, Pile A. 1985. Upregulation of gamma-aminobutyric acid (GABA) B binding sites in rat frontal cortex: a common action of repeated administration of different classes of antidepressants and electroshock. J Pharmacol Exp Ther 235: 191-199.
179. Lloyd KG, Zivkovic B, Sanger D, Depoortere H, Bartholini G. 1987. Fengabine, a novel antidepressant GABAergic agent. I. Activity in models for antidepressant drugs and psychopharmacological profile. J Pharmacol Exp Ther 241:245-250.
180. Lloyd KG, Zivkovic B, Scatton B, Morselli PL, Bartholini G. 1989. The gabaergic hypothesis of depression. Prog Neuropsychopharmacol Biol Psychiatry 13:341-351.
181. Lofberg C, Agren H, Harro J, Oreland L. 1998. Cholecystokinin in CSF from depressed patients: possible relations to severity of depression and suicidal behavior. Eur Neuropsychopharmacol 8: 153-157.
182. Lopez JF, Akil H, Watson SJ. 1999. Neural circuits mediating stress. Biol Psychiatry 46:1461-1471.
183. Lundorf MD, Buttenschon HN, Foldagen L, Blackwood DH, Muir WL, Murray V, Pelose AJ, Kruse TA, Ewald H, Mors O. 2005. Mutational screening and association study of glutamate decarboxylase 1 as a candidate susceptibility gene for bipolar disorders and schizophrenia. Am J Med Genet 135:94-101.
184. Lydiard RB. 2003. The role of GABA in anxiety disorders. J Clin Psychiatry 64(Suppl 3):21-27.
185. Maihofner C, Ropohl A, Reulbach U, Hiller M, Elstner S, Kornhuber J, Sperling W 2005. Effects of repetitive transcranial magnetic stimulation in depression: a magnetoencephalographic study. Neuroreport 16:1839-1842.
186. Malatynska E, De Leon I, Allen D, Yamamura HI. 1995. Effects of amitriptyline on GABA-stimulated 36CI-uptake in relation to a behavioral model of depression. Brain Res Bull 37:53-59.
187. Malatynska E, Crites GJ, Harrawood D, Goldenberg R, Matheson GK. 2000. Antidepressant effects on GABA-stimulated 36Cl(-) influx in rat cerebral cortex are altered after treatment with GABA(A) receptor antisense oligodeoxynucleotides. Brain Res 869:78-84.
188. Malhi GS, Lagopoulos J, Ward PB, Kumari V, Mitchell PB, Parker GB, Ivanovski B, Sachdev P. 2004. Cognitive generation of affect in bipolar depression: an fMRI study. Eur J Neurosci 19: 741-754.
189. Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. 1998. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 55:715-720.
190. Marowsky A, Fritschy JM, Vogl KE. 2004. Functional mapping of GABAA receptor subtypes in the amygdala. Eur J Neurosci 20: 1281-1289.
191. Martin SC, Russek SJ, Farb DH. 2001. Human GABAbR genomic structure: evidence for splice variants in GABAbR1 but not GABAbR2. Gene 278:63-79.
192. Massat I, Souery D, Del-Favero J, Oruc L, Noethen MM, Blackwood D, Thomson M, Muir W, Papadimitrious GN, Dikeos DG, Kaneva R, Seretti A, Lilli A, Smeraldi E, Jakovljevic M, Folnegovic V, Rietscheli M, Milanova V, Valente F, Van Broeckhoven C, Mendlewicz J. 2002. Excess of allele 1 for α3 subunit GABA receptor gene (GABRA3) in bipolar patients: a multicentric association study. Mol Psychiatry 7:201-207.
193. Matsubara M, Suzuki S, Miura K, Terashima M, Sugita S, Kimura H, Hatsuda S, Mori T, Murakami H, Hayashi T, Ohta T, Ohara M. 2000. Electrophysiologic analysis of antidepressant drug effects on the GABA(A) receptor complex based upon antagonist-induced encephalographic power spectrum changes. Neuropsychobiology 42: 149-157.
194. Maurice T. 2004. Neurosteroids and sigma1 receptors, biochemical and behavioral relevance. Pharmacopsychiatry 37(Suppl 3): S171-S182.
195. McKinney WT. 2004. Overview of the past contributions in animal models and their changing place in psychiatry. Semin Clin Psychiatry 6:68-78.
196. Medina JH, Novas ML, Wolfman CN, Levi de Stein M, De Robertis E. 1983. Benzodiazepine receptors in rat cerebelar cortex and hippocampus undergo rapid and reversible changes after acute stress. Neuroscience 9:331-335.
197. Mei B, Li C, Dong S, Jiang CH, Wang H, Hu Y. 2005. Distinct gene expression profiles in hippocampus and amygdala after fear conditioning. Brain Res Bull 67:1-12.
198. Mervaala E, Kononen M, Fohr J, Husso-Saastamoinen M, Valkonen-Korhonen M, Kuikka JT, Viinamaki H, Tammi AK, Tiihonen J, Partanen J, Lehtonen J. 2001. SPECT and neuropsychological performance in severe depression treated with ECT. J Affect Disord 66:47-58.
199. Michael N, Erfurth A, Ohrmann P, Arolt V, Heindel W, Pfleiderer B. 2003. Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression. Psychol Med 33: 1277-1284.
200. Mihalek RM, Banerjee PK, Korpi ER, Quinlan JJ, Firestone LL, Mi ZP, Lagenaur C, Tretter V, Sieghart W, Anagnostaras SG. 1999. Attenuated sensitivity to neuroactive steroids in gamma-aminobutyrate type A receptor delta subunit knockout mice. Proc Natl Acad Sci USA 96:12905-12910.
201. Mindus P, Ericson K, Greitz T, Meyerson BA, Nyman H, Sjogren I. 1986. Regional cerebral glucose metabolism in anxiety disorders studied with positron emission tomography before and after psychosurgical intervention. A preliminary report. Acta Radiol Suppl 369:444-448.
202. MGI. 2006. Mouse Genome Informatics, http://www.informatics.jax.org/ Jackson Laboratory, Bar Harbor, ME.
203. Mohler H, Fritschy JM, Hensch T, Rudolph U. 2004. Specific GABAa circuits in brain development and therapy. Biochem Pharmacol 68:1685-1690.
204. Mombereau C, Kaupmann K, Froestl W, Sansig G, van der Putten H, Cryan JE 2004. Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology 29: 1050-1062.
205. Mombereau C, Kaupmann K, Gassmann M, Bettler B, van der Putten H, Cryan JE 2005. Altered anxiety and depression-related behaviors in mice lacking GABA-B(2) receptor subunits. Neuroreport 16:307-310.
206. Montpied P, Weizman A, Weizman R, Kook KA, Morrow AL, Paul SM. 1993. Repeated swim-stress reduces GABAA receptor alpha subunit mRNAs in the mouse hippocampus. Mol Brain Res 18: 267-272.
207. Morris JS, Friston KJ, Buchel C, Frith CD, Young AW, Calder AJ, Dolan RJ. 1998. A neuromodulatory role for the human amygdala in processing emotional facial expressions. Brain 121:47-57.
208. Nakagawa Y, Ishima T, Ishibashi Y, Yoshii T, Takashima T 1996a. Involvement of GABA(B) receptor systems in action of antidepressants: baclofen but not bicuculline attenuates the effects of antidepressants on the forced swim test in rats. Brain Res 709: 215-220.
209. Nakagawa Y, Ishima T, Ishibashi Y, Yoshii T, Takashima T 1996b. Involvement of GABA(B) receptor systems in action of antidepressants: baclofen but not bicuculline attenuates the effects of antidepressants on the forced swim test in rats. Brain Res 741: 240-245.
210. Nashold BC, Wilson WP, Slaughter DG. 1969. Sensations evoked by stimulation in the midbrain of man. J Neurosurg 30:14-24.
211. Nemeroff CB. 2003. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull 37: 133-146.
212. Nestler EJ, Gould E, Manji H, Buncan M, Duman RS, Greshenfeld HK, Hen R, Koester S, Lederhendler I, Meaney M, Robbins T, Winsky L, Zalcman S. 2002. Preclinical models: status of basic research in depression. Biol Psychiatry 52:503-528.
213. Neumeister A, Wood S, Bonne O, Nugent AC, Luckenhaugh DA, Young T, Bain EE, Charney DS, Drevets WC. 2005. Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol Psychiatry 57:935-937.
214. Nishimura H, Tanaka M. 1992. Effects of alprazolam on anxiety-related behavior of rats in a modified forced-swim test employing straw suspension. Pharmacol Biochem Behav 41:425-427.
215. Nishimura H, Ida Y, Tsuda A, Tanaka M. 1989. Opposite effects of diazepam and beta-CCE on immobility and straw-climbing behavior of rats in a modified forced-swim test. Pharmacol Biochem Behav 33:227-231.
216. Nobre MJ, Brandao ML. 2004. Analysis of freezing behavior and ultrasonic vocalization in response to foot-shocks, ultrasound signals and GABAergic inhibition in the inferior colliculus: effects of muscimol and midazolam. Eur Neuropsychophannacol 14: 45-52.
217. Nutt D. 2000. Treatment of depression and concomitant anxiety. Eur Neuropsychophannacol 10(Suppl 4):S433-S437.
218. Nutt DJ. 2001. Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry 62(Suppl 11):22-27.
219. Nutt DJ. 2005. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectrums 10:49-56.
220. Nutt DJ, Malizia AL. 2001. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 179:390-396.
221. Nutt DJ, Ballenger JC, Sheehan D, Wittchen HU. 2002. Generalized anxiety disorder: comorbidity, comparative biology and treatment. Int J Neuropsychophannacol 5:315-325.
222. Obrocea GV, Dunn RM, Frye MA, Ketter TA, Luckenbaugh DA, Leverich GS, Speer .AM, Osuch EA, Jajodia K, Post RM. 2002. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 51: 253-260.
223. O'Connor WT, Earley B, Leonard BE. 1985. Antidepressant properties of the triazolobenzodiazepines alprazolam and adinazolain: studies on the olfactory bulbectomized rat model of depression. Br J Clin Pharmacol 19(Suppl 1):49S-56S.
224. Olsen RW, Sapp DM. 1995. Neuroactive steroid modulation of GABAA receptors. Adv Biochem Psychopharmacol 48:57-74.
225. Olsen RW, Sapp DM, Bureau MH, Turner DM, Kokka N. 1991. Allosteric actions of central nervous system depressants including anesthetics on subtypes of the inhibitory gamma-aminobutyric acid A receptor-chloride channel complex. Ann N Y Acad Sci 625: 145-154.
226. Olsen RW, Chang CS, Li G, Hanchar HJ, Wallner M. 2004. Fishing for allosteric sites on GABA(A) receptors. Biochem Pharmacol 68: 1675-1684.
227. Ong J, Kerr DI. 2005. Clinical potential of GABA(B) receptor modulators. CNS Drug Rev 11:317-334.
228. Oruc L, Verheyen GR, Furac I, Ivezic S, Jakovljevic M, Raeymaekers P, Van Broeckhoven C. 1997. Positive association between the GABRA5 gene and unipolar recurrent major depression. Neuropsychobiology 36:62-64.
229. O'Sullivan K. 1984. Depression and its treatment in alcoholics: a review. Can J Psychiatry 29:379-384.
230. Pandossio JE, Molina VA, Brandao ML. 2000. Prior electrical stimulation of the inferior colliculus sensitizes rats to the stress of the elevated plus-maze test. Behav Brain Res 109: 19-25.
231. Papadimitriou GN, Dikeos DG, Karadima G, Avramopolous D, Daskalopoulou EG, Vassilopoulos D, Stefanis CN. 1998. Association between the GABAA receptor α5 subunit gene locus (GABRA5) and dipolar affective disorder. Am J Med Genet 81: 73-80.
232. Petty F. 1995. GABA and mood disorders: a brief review and hypothesis. J Affect Disord 34:275-281.
233. Petty F, Sherman AD. 1981. GABAergic modulation of learned helplessness. Pharmacol Biochem Behav 15:567-570.
234. Petty F, Kramer GL, Dunnam D, Rush AJ. 1990. Plasma GABA in mood disorders. Psychopharmacol Bull 26:157-161.
235. Petty F, Kramer GL, Fulton M, Moeller FG, Rush AJ. 1993. Low plasma GABA is a trait-like marker for bipolar illness. Neuropsychopharmacology 9:125-132.
236. Petty F, Trivedi MH, Fulton M, Rush AJ. 1995. Benzodiazepines as antidepressants: does GABA play a role in depression? Biol Psychiatry 38:578-591.
237. Phelps EA, O'Connor KJ, Gatenby C, Gore JC, Grillon C, Davis M. 2001. Activation of the left amygdala to a cognitive representation of fear. Nat Neurosci 4:437-441.
238. Pile A, Nowak G. 2005. GABAergic hypotheses of anxiety and depression: Focus on GABA(B) receptors. Drugs Today 41: 755-766.
239. Post RM. 2004. Differing psychotropic profiles of anticonvulsants in bipolar and other psychiatric disorders. Clin Neurosci Res 4: 9-30.
240. Post RM, Ketter TA, Joffe RT, Krainlinger KL. 1991. Lack of beneficial effects of l-baclofen in affective disorder. Int Clin Psychopharmacol 6:197-207.
241. Post RM, Denicoff KD, Frye MA, Dunn RT, Leverich GS, Osuch E, Speer A. 1998. A history of the use of anticonvulsants as mood stabilizers in the last two decades of the 20th century. Neuropsychobiology 38:152-166.
242. Quirk GJ, Gehlert DR. 2003. Inhibition of the amygdala: key to pathological states? Ann N Y Acad Sci 985:263-272.
243. Raghavendra V, Kaur G, Kulkarni SK. 2000. Anti-depressant action of melatonin in chronic forced swimming-induced behavioral despair in mice, role of peripheral benzodiazepine receptor modulation. Eur Neuropsychophannacol 10:473-481.
244. Rago L, Kiivet RA, Adojaan A, Harro J, Allikmets L. 1990. Stress-protection action of beta-phenyl(GABA): involvement of central and peripheral type benzodiazepine binding sites. Pharmacol Toxicol 66:41-44.
245. Rajkowska G. 2003. Depression: what we can learn from postmortem studies. Neuroscientist 9:273-284.
246. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA. 1999. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 45: 1085-1098.
247. Rapaport MH, Clary C, Fayyad R, Endicott J. 2005. Quality-of-life impainnent in depressive and anxiety disorders. Am J Psychiatry 162: 1171-1178.
248. Rauch SL, van der Kolk BA, Fisler RE, Alpert NM, Orr SP, Savage CR, Fischman AJ, Jenike MA, Pitman RK. 1996. A symptom provocation study of posttraumatic stress disorder using positron emission tomography and script-driven imagery. Arch Gen Psychiatry 53:380-387.
249. Reddy DS. 2003. Is there a physiological role for the neurosteroid THDOC in stress-sensitive conditions? Trends Pharmacol Sci 24: 103-106.
250. Reddy DS, O'Malley BW, Rogawski MA. 2005. Anxiolytic activity of progesterone in progesterone receptor knockout mice. Neuropharmacology 48:14-24.
251. Ring HA, Crellin R, Kirker S, Reynolds EH. 1993. Vigabatrin and depression. J Neurol Neurosurg Psychiatry 56:925-928.
252. Rochet T, Tonon MC, Kopp N, Vaudry H, Miachon S. 1998. Evaluation of endozepine-like immunoreactivity in the frontal cortex of suicide victims. Neuroreport 9:53-56.
253. Rodgers RJ. 1997. Animal models of 'anxiety': where next? Behav Pharmacol 8:477-496.
254. Rodin E. 1958. Metrazol tolerance in a normal volunteer population; an investigation of the potential significance of abnormal findings. EEG Clin Neurophysiol Suppl 10:433-446.
255. Rodin E. 1970. Metrazol tolerance in a "nonnal" volunteer population. A ten year follow-up report. J Nerv Ment Dis 150:438-443.
256. Rogawski MA, Loscher W 2004. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 10:685-692.
257. Rosahl TW. 2003. Validation of GABAa receptor subtypes as potential drug targets by using genetically modified mice. Curr Drug Targets CNS Neurol Disord 2:207-212.
258. Rosenthal M. 2003. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 64: 1245-1249.
259. Rossini D, Lucca A, Zanardi R, Magri L, Smcraldi E. 2005. Transcranial magnetic stimulation in treatment-resistant depressed patients: a double-blind, placebo-controlled trial. Psychiatry Res 137: 1-10.
260. Rosso IM, Cintron CM, Steingard RJ, Renshaw PF, Young AD, Yurgelun-Todd DA. 2005. Amygdala and hippocampus volumes in pediatric major depression. Biol Psychiatry 57:21-26.
261. Roy A. 1991. Cerebrospinal fluid diazepam binding inhibitor in depressed patients and normal controls. Neuropharmacology 30: 1441-1444.
262. Roy A, DeJong J, Lamparski D, George T, Linnoila M. 1991. Depression among alcoholics. Relationship to clinical and cerebrospinal fluid variables. Arch Gen Psychiatry 48:428-432.
263. Roy MA, Neale MC, Pedersen NL, Marie AA, Kendler KS. 1995. A twin study of generalized anxiety disorder and major depression. Psychol Med 25:1037-1049.
264. Rudolph U, Mohler H. 2006. GABA-based therapeutic approaches: GABAa receptor subtype functions. Curr Opin Pharmacol 6:1-6.
265. Rupniak NM. 2003. Animal models of depression: challenges from a drug development perspective. Behav Pharmacol 14:385-390.
266. Rupprecht R. 2003. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology 28:139-168.
267. Sajdyk TJ, Shekhar A. 2000. Sodium lactate elicits anxiety in rats after repeated GABA receptor blockade in the basolateral amygdala. Eur J Pharmacol 394:265-273.
268. Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA, Berman RM, Charney DS, Krystal JH. 1999. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 56: 1043-1047.
269. Sanacora G, Mason GF, Krystal JH. 2000. Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. Crit Rev Neurobiol 14:23-45.
270. Sanacora G, Mason GF, Rothman DL, Krystal JH. 2002. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 159:663-665.
271. Sanacora G, Mason GF, Rothman DL, Hyder F, Ciarcia JJ, Ostroff RB, Berman RM, Krystal JH. 2003. Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry 160:577-579.
272. Sanacora G, Fenton LR, Fasula MK, Rothman DL, Levin Y, Krystal JH, Mason GE 2006. Cortical gamma-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy. Biol Psychiatry 59:284-286.
273. Sand PG, Godau C, Riederer P, Peters C, Franke P, Nothen MM, Stober G, Fritze J, Maier W, Propping P, Lesch KP, Riess O, Sander T, Beckmann H, Decken J. 2000. Exonic variants of the GABA(B) receptor gene and panic disorder. Psychiatr Genet 10: 191-194.
274. Sandford JJ, Argyropoulos SV, Nutt DJ. 2000. The psychobiology of anxiolytic drug. 1. Basic neurobiology. Pharmacol Ther 88: 197-212.
275. Sands SA, Reisman SA, Enna SJ. 2004. Effect of antidepressants on GABA(B) receptor function and subunit expression in rat hippocampus. Biochem Pharmacol 68:1489-1495.
276. Samp A, Larsson OM, Schousboe A. 2003. GABA transporters and GABA-transaminase as drug targets. Curr Drug Target CNS Neurol Disord 2:269-277.
277. Saylam C, Ucerler H, Kitis O, Ozand E, Gonul AS. 2006. Reduced hippocampal volume in drug-free depressed patients. Surg Radiol Anat 28:82-87.
278. Schaller JL, Thomas J, Rawlings D. 2004. Low-dose tiagabine effectiveness in anxiety disorders. MedGenMed 6:8.
279. Schaffer LC, Schaffer CB, Howe J. 2002. An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients. J Affect Disord 71:259-263.
280. Schechter MD, Chance WT. 1979. Non-specificity of "behavioral despair" as an animal model of depression. Eur J Pharmacol 60: 139-142.
281. Schenber LC, Graeff FG. 1978. Role of the periaqueductal gray substance in the antianxiety action of benzodiazepines. Pharmacol Biochem Behav 9:287-295.
282. Schmitt U, Hiemke C. 1999. Effects of GABA-transporter (GAT) inhibitors on rat behavior in open field and elevated plus maze. Behav Pharmacol 10:131-137.
283. Schmitt U, Luddens H, Hiemke C. 2002. Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats. J Neural Transm 109:871-880.
284. Schousboe A, Sarup A, Larsson OM, White HS. 2004. GABA transporters as drug targets for modulation of GABAergic activity. Biochem Pharmacol 68:1557-1563.
285. Schwartz TL. 2002. The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series. Psychopharmacol Bull 36:53-57.
286. Sen S, Villafuerte S, Nesse R, Stoltenberg SF, Hopcian J, Cleiberman L, Weder A, Burmeister M. 2004. Serotonin transporter and GABAA alpha 6 receptor variants are associated with neuroticism. Biol Psychiatry 55:244-249.
287. Shah AA, Sjovold T, Treit D. 2004. Inactivation of the medial prefrontal cortex with the GABAA receptor agonist muscimol increases open-arm activity in the elevated plus-maze and attenuates shock-probe burying in rats. Brain Res 1028:112-115.
288. Shekhar A, Keim SR, Simon JR, McBride WJ. 1996. Dorsomedial hypothalamic GABA dysfunction produces physiological arousal following sodium lactate infusions. Pharmacol Biochem Behav 55: 249-256.
289. Sheline YI. 2003. Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry 54:338-352.
290. Shelton RC. 2003. Treating bipolar depression. J Fam Pract Suppl S14-S17.
291. Shephard RA, Wedlock P, Wilson NE. 1992. Direct evidence for mediation of an anticonflict effect of baclofen by GABAb receptors. Pharmacol Biochem Behav 41:651-653.
292. Sherif F, Oreland L. 1995. Effect of the GABA-transaminase inhibitor vigabatrin on exploratory behavior in socially isolated rats. Behav Brain Res 72:135-140.
293. Shiah IS, Yatham LN. 1998. GABA function in mood disorders: an update and critical review. Life Sci 63:1289-1303.
294. Shibata S, Nakanishi H, Watanabe S, Ueki S. 1984. Effects of chronic administration of antidepressants on mouse-killing behavior (muricide) in olfactory bulbectomized rats. Pharmacol Biochem Behav 21:225-230.
295. Sieghart W. 1995. Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. Pharmacol Rev 47: 181-234.
296. Sieghart W, Fuchs K, Tretter V, Ebert V, Jechlinger M, Hoger H, Adamiker D. 1999. Structure and subunit composition of GABA(A) receptors. Neurochem Int 34:379-385.
297. Singewald N, Salchner P, Sharp T. 2003. Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol Psychiatry 53:275-283.
298. Skrebuhhova T, Allikmets L, Matto V. 1999. Effects of anxiogenic drugs in rat forced swimming test. Methods Find Exp Clin Pharmacol 21:173-178.
299. Smoller JW, Rosenbaum JF, Biedennan J, Susswein LS, Kennedy J, Kagan J, Snidman N, Laird N, Tsuang MT, Faraone SV, Schwarz A, Slaugenhaupt SA. 2001. Genetic association analysis of behavioral inhibition using candidate loci from mouse models. Am J Med Genet 105:226-235.
300. Spivak B, Maayan R, Kotier M, Mester R, Gil-Ad I, Shtaif B, Weizman A. 2000. Elevated circulatory level of GABA(A) - antagonistic neurosteroids in patients with combat-related posttraumatic stress disorder. Psychol Med 30:1227-1231.
301. Stahl SM. 2004. Anticonvulsants as anxiolytics. 1. Tiagabine and other anticonvulsants with actions on GABA. J Clin Psychiatry 65:291-292.
302. Stork O, Ji FY, Kaneko K, Stork S, Yoshinobu Y, Moriya T, Shibata S, Obata K. 2000. Postnatal development of a GABA deficit and disturbance of neural functions in mice lacking GAD65. Brain Res 865:45-58.
303. Stork O, Ji FY, Obata K. 2002. Reduction of extracellular GABA in the mouse amygdala during and following confrontation with a conditioned fear stimulus. Neurosci Lett 327:138-142.
304. Strakowski SM, Adler CM, DelBello MP. 2002. Volumetric MRI studies of mood disorders: do they distinguish unipolar and bipolar disorder? Bipolar Disord 4:80-88.
305. Strohle A, Romeo E, Hermann B, Pasini A, Spalletta G, di Michele F, Holsboer F, Rupprecht R. 1999. Concentrations of 3 alpha-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiatry 45:274-277.
306. Sundman I, Allard P, Eriksson A, Marcusson J. 1997. GABA uptake sites in frontal cortex from suicide victims and in aging. Neuropsychobiology 35:11-15.
307. Sundman-Eriksson I, Allard P. 2002. ([3]H)Tiagabine binding to GABA transporter-1 (GAT-I) in suicidal depression. J Affect Disord 71:29-33.
308. Sundstrom I, Ashbrook D, Backstrom T. 1997. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology 22:25-38.
309. Sundstrom-Poromaa I, Smith S, Gulinello M. 2003. GABA receptors, progesterone and premenstrual dysphoric disorder. Arch Women Mem Health 6:23-41.
310. Szymczyk G, Zebrowska-Lupina I. 2000. Influence of antiepileptics on efficacy of antidepressant drugs in forced swimming test. Pol J Pharmacol 52:337-344.
311. Tanay VAMI, Glencorse TA, Greenshaw AJ, Baker GB, Bateson AN. 1996. Chronic administration of antipanic drugs alters rat brainstem GABAa receptor subunit mRNA levels. Neuropharmacology 35:1475-1482.
312. Tanay VAMI, Greenshaw AJ, Baker GB, Bateson AN. 2001. Common effects of chronically administered antipanic drugs on brainstem GABAA receptor subunit gene expression. Mol Psychiatry 6:404-412.
313. Tunnicliff G, Malatynska E. 2003. Central GABAergic systems and depressive illness. Neurochem Res 28:965-976.
314. Turner DM, Ransom RW, Yang JS, Olsen RW. 1989. Steroid anesthetics and naturally occurring analogs modulate the gamma-aminobutyric acid receptor complex at a site distinct from barbiturates. J Pharmacol Exp Ther 248:960-966.
315. Uhart M, McCaul ME, Oswald LM, Choi L, Wand GS. 2004. GABRA6 gene polymorphism and an attenuated stress response. Mol Psychiatry 9:998-1006.
316. Umezu T 1999. Effects of psychoactive drugs in the Vogel conflict test in mice. Jpn J Pharmacol 80:111-118.
317. Ungard JT, Beekman M, Gasior M, Carter RB, Dijkstra D, Witkin JM. 2000. Modification of behavioral effects of drugs in mice by neuroactive steroids. Psychopharmacology (Berl) 148:336-343.
318. Urani A, Roman FJ, Phan VL, Su TP, Maurice T. 2001. The antidepressant-like effect induced by sigma(1)-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 298:1269-1279.
319. Urani A, Chourbaji S, Gass P. 2005. Mutant mouse models of depression: candidate genes and current mouse lines. Neurosci Biobehav Rev 29:805-828.
320. Uzunov DP, Cooper TB, Costa E, Guidotti A. 1996. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc Natl Acad Sci USA 93: 12599-12604.
321. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A. 1998. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 95: 3239-3244.
322. Uzunova V, Ceci M, Kohler C, Uzunov DP, Wrynn AS. 2003. Region-specific dysregulation of allopregnanolone brain content in the olfactory bulbectomized rat model of depression. Brain Res 976: 1-8.
323. Uzunova V, Wrynn AS, Kinnunen A, Ceci M, Kohler C, Uzunov DP. 2004. Chronic antidepressants reverse cerebrocortical allopregnanolone decline in the olfactory-bulbectomized rat. Eur J Pharmacol 486:31-34.
324. Vaiva G, Thomas P, Ducrocq F, Fontaine M, Boss V, Devos P, Rascle C, Cottencin O, Brunet A, Laffargue P, Goudemand M. 2004. Low posttrauma GABA plasma levels as a predictive factor in the development of acute posttraumatic stress disorder. Biol Psychiatry 55: 250-254.
325. Vekovisheva OYu. 2003. The role of a6 subunit-containing GABAa receptors in behavioral effects of alcohol and drug treatments. Acta Univer Tamper 928:1-58.
326. Verkuyl JM, Hemby SE, Joels M. 2004. Chronic stress attenuates GABAergic inhibition and alters gene expression of parvocellular neurons in rat hypothalamus. Eur J Neurosci 20:1665-1673.
327. Villafuerte S, Burmeister M. 2003. Untangling genetic networks of panic, phobia, fear and anxiety. Genome Biol 4:224.1-4.
328. Wang PW, Ketter TA. 2005. Clinical use of carbamazepine for bipolar disorders. Expert Opin Pharmacother 6:2887-2902.
329. Wang H, Zhu YZ, Wong PTH, Farook JM, Teo AL, Lee LKH, Moochhala S. 2003. cDNA microarray analysis of gene expression in anxious PVG and SD rats after cat-freezing test. Exp Brain Res 149: 413-421.
330. Weizman R, Weizman A, Kook KA, Vocci F, Deutsch SI, Paul SM. 1989. Repeated swim stress alters brain benzodiazepine receptors measured in vivo. J Pharmacol Exp Ther 249:701-707.
331. Whiting PJ. 2003. GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery? Drug Discov Today 8: 445-450.
332. Wik G, Fredrikson M, Ericson K, Eriksson L, Stone-Elander S, Greitz T 1993. A functional cerebral response to frightening visual stimulation. Psychiatry Res 50:15-24.
333. Williams SM, Bryan-Lluka LJ, Pow DV. 2005. Quantitative analysis of immunolabeling for serotonin and for glutamate transporters after administration of imipramine and citalopram. Brain Res 1042: 224-232.
334. Wong ML, Licinio J. 2004. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov 3:136-151.
335. Wu JC, Buchsbaum MS, Hershey TG, Hazlett E, Sicotte N, Johnson JC. 1991. PET in generalized anxiety disorder. Biol Psychiatry 29: 1181-1199.
336. Yamada K, Watanabe A, Iwayama-Shigeno Y, Yoshikawa T. 2003. Evidence of association between γ-aminobutyric acid type A receptor genes located on 5q34 and female patients with mood disorders. Neurosci Lett 349:9-12.
337. Yang J, Shen J. 2005. In vivo evidence for reduced cortical glutamate-glutamine cycling in rats treated with the antidepressant/antipanic drug phenelzine. Neuroscience 135:927-937.
338. Yilmazer-Hanke DM, Roskoden T, Zilles K, Schwegler H. 2003. Anxiety-related behavior and densities of glutamate, GABAA, acetylcholine and serotonin receptors in the amygdala of seven inbred mouse strains. Behav Brain Res 145:145-159.
339. Yoshikawa T, Watanabe A, Ishitsuka Y, Nakaya A, Nakatani N. 2002. Identification of multiple genetic loci linked to the propensity for "behavioral despair" in mice. Genome Res 12:357-366.
340. Yurgelun-Todd DA, Gruber SA, Kanayama G, Killgore WD, Baird AA, Young AD. 2000. fMRI during affect discrimination in bipolar affective disorder. Bipolar Disord 2:237-248.
341. Zarrindast M, Rostami P, Sadeghi-Hariri M. 2001. GABA(A) but not GABA(B) receptor stimulation induces antianxiety profile in rats. Pharmacol Biochem Behav 69:9-15.
342. Zhang L, Rubinow DR, Ma W, Marks JM, Feldman AN, Barker JL, Tathan TA. 1998. GABA receptor subunit mRNA expression in brain of conflict, yoked control and control rats. Mol Brain Res 58: 16-26.
343. Zimmerberg B, Brunelli SA, Fluty AJ, Frye CA. 2005. Differences in affective behaviors and hippocampal allopregnanolone levels in adult rats of lines selectively bred for infantile vocalizations. Behav Brain Res 159:301-311.
344. Zwanzger P, Rupprecht R. 2005. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci 30:167-175.